Threat∑DerivedConfidence: ModerateSnapshot Nov 8, 2026 · assessed Nov 8, 2026
The most common stated reason among 1,113 current FDA shortage entries is "Not stated" (678)
Composition of shortage_reason among Current openFDA drug shortage records. Reasons are manufacturer-reported categories; many entries state no reason.
Why this matters
Stated reasons separate demand surges from manufacturing, quality, and discontinuation causes, which call for different resilience responses.
What the evidence says
Not stated: 678.
Other: 164.
Demand increase for the drug: 126.
Shortage of an active ingredient: 61.
Discontinuation of the manufacture of the drug: 46.
Delay in shipping of the drug: 21.
Requirements related to complying with good manufacturing practices: 14.
Regulatory delay: 2.
Routes of administration among Current entries: INTRAVENOUS 300, ORAL 228, INTRAMUSCULAR 175, Not stated 173.
Not stated678
Other164
Demand increase for the drug126
Shortage of an active ingredient61
Discontinuation of the manufacture of the drug46
Delay in shipping of the drug21
Stated shortage reasons among Current entries.
Category
count
Not stated
678
Other
164
Demand increase for the drug
126
Shortage of an active ingredient
61
Discontinuation of the manufacture of the drug
46
Delay in shipping of the drug
21
Stated shortage reasons among Current entries.
What remains uncertain
Reason fields are free-text categories chosen by reporters.
Package-level entries inflate counts for multi-presentation products.
Not a measure of clinical impact or national availability.
Scoring and methodology
SupplyFragility: Not scored(bm-scoring-0.1; factor completeness 20%)
Only documented_disruption has an input; lead time and substitutability are unavailable, so no composite is published.
Factor
Weight
Value
Definition
concentration
0.25
unknown
Observed supplier or country concentration.
documented_disruption
0.2
1
Supported disruption incidents in the period.
lead_time_stress
0.2
unknown
Observed lead-time stress (often unavailable).
limited_substitutability
0.15
unknown
Documented scarcity of substitutes.
geographic_exposure
0.1
unknown
Geographic exposure at safe granularity.
digital_dependency_risk
0.1
unknown
Declared software component risk.
Timeline
published
Upstream last updated · Nov 6, 2026
retrieved
Retrieved · Nov 8, 2026
assessed
Assessed · Nov 8, 2026
Event, published, retrieved, and assessed times are stored separately and never conflated.
Explore the relationships
Related insights are linked only through shared sources or mapped topics. Open the evidence graph.
What to investigate next
Deduplicate to product level.
Join USGS and trade data for upstream input concentration once connectors are active.
An HHI computed over manufacturer shares of Current shortage postings. This is a reporting-share concentration, not a market-share HHI, and says nothing about who supplies the market.
Fresenius Kabi USA, LLC146
Hospira, Inc.129
Hikma Pharmaceuticals USA …76
Baxter Healthcare Corporat…45
Eugia US LLC42
Current shortage postings by manufacturer (top 6).
Category
count
Fresenius Kabi USA, LLC
146
Hospira, Inc.
129
Hikma Pharmaceuticals USA …
76
Baxter Healthcare Corporat…
45
Eugia US LLC
42
Current shortage postings by manufacturer (top 6).
Count of openFDA drug shortage records with status Current (upstream last updated 2026-11-06). Entries are product-level postings, not patient-level impact.
Anesthesia359
Pediatric227
Psychiatry220
Gastroenterology134
Analgesia/Addiction126
Current shortage entries by therapeutic category (top 8).
Category
count
Anesthesia
359
Pediatric
227
Psychiatry
220
Gastroenterology
134
Analgesia/Addiction
126
Current shortage entries by therapeutic category (top 8).